The Intermountain Healthcare Cancer Center in Utah received a three-year accreditation from the Commission on Cancer, a quality assurance program of the American College of Surgeons.
Radiation oncologists met with congressional leaders and staff May 17 to ask for their support of policies to bolster access and equity in cancer care, as part of the American Society for Radiation Oncology Advocacy Day.
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, according to a large epidemiologic study led by NCI researchers.
A study led by researchers at the American Cancer Society showed Medicaid expansion under the Affordable Care Act was associated with an increase in two-year overall survival rates among patients newly diagnosed with cancer, especially among non-Hispanic Black people and people living in rural areas.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult cancer survivors of acute lymphoblastic leukemia and acute myeloid leukemia have reduced long-term survival rates compared to their peers without cancer.
Patients with head and neck cancer undergoing radiation therapy are less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, according to a study led by radiation oncologists at Roswell Park Comprehensive Cancer Center.
“Polypharmacy,” or the concurrent use of multiple medications, can lead to harmful drug interactions—which is especially dangerous for cancer patients about to undergo therapy, according to a study led by Wilmot Cancer Institute researchers.
Latest results from the phase III IKEMA clinical trial evaluating the monoclonal antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (HR: 0.58; 95% CI: 25.8-44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8-25.1; n=123), in patients with relapsed multiple myeloma.
Paige received CE-IVD and UKCA marks for the Paige Prostate Biomarker Suite, an AI software designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin. This is Paige’s first European regulatory certification of image-based biomarker detection on H&E-stained tissue samples.
The same House appropriators who, with bipartisan resolve, oversaw years of dramatic funding increases for NIH expressed equally bipartisan misgivings about President Joe Biden’s proposal to boost funding for the Advanced Research Projects Agency for Health while giving NIH a meager raise—and cutting funds for NCI.
